ArticleMolecular biology reports2025
Circulating plasma microRNA expression profile: potential minimally invasive biomarker for early detection of coronary artery disease development.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- MicroRNA Signatures in Cardiometabolic Disorders as a Next-Generation Diagnostic Approach: Current Insight.International journal of molecular sciences · 2025Review
- The Heart's Small Molecules: The Importance of MicroRNAs in Cardiovascular Health.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe prevalence of coronary artery disease (CAD) is increasing among young adults. To improve CAD diagnosis, microRNAs are being explored as potential minimally invasive biomarkers. The aim of this study was to evaluate circulating microRNA (miRNA) expression profiles and assess their value in predicting the development of early-onset CAD. METHODS AND
resultsA total of 108 patients with early- and late-onset CAD and 29 individuals without CAD were included, and their miRNA expression was evaluated. The diagnostic value of differentially expressed miRNAs across the subgroups was tested by logistic regression models and ROC curve analysis. A total of 287 different circulating miRNAs were analysed following sequencing and preprocessing. Seven miRNAs (miR-10b-5p, miR-29c-3p, miR-142-5p, miR-320b, miR-451a, miR-486-3p, and miR-625-3p) were found to be differentially expressed across all the study groups, four of which (miR-142-5p, miR-29c-3p, miR-451a, and miR-486-3p) were significantly downregulated in the late-onset CAD group compared with the control group. ROC analysis demonstrated that the combination of the seven miRNAs had high diagnostic accuracy, with an AUC of 0.9924 for distinguishing late-onset CAD from the other groups, and moderate accuracy, with an AUC of 0.8235 for distinguishing early-onset CAD from the other groups.
conclusionsA combination of seven circulating miRNAs (miR-10b-5p, miR-29c-3p, miR-142-5p, miR-320b, miR-451a, miR-486-3p, and miR-625-3p) is a promising biomarker panel for CAD diagnosis, distinguishing between early-onset and late-onset disease. While the panel demonstrated high accuracy in classifying late-onset CAD, its ability to predict early-onset CAD requires further validation. Larger, independent populations are needed to validate the predictive ability of the panel for early disease detection, confirm these findings, and improve generalizability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.